β2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies

Arthritis and Rheumatism

Volumn 42, Issue 1, 1999, Pages 167-174

  Ieko, Masahiro ^a   Ichikawa, Kenji ^b   Triplett, Douglas A ^c   Matsuura, Eiji ^d   Atsumi, Tatsuya ^b   Sawada, Ken Ichi ^b   Koike, Takao ^b  

^a HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c BALL MEMORIAL HOSPITAL   (United States)

^d OKAYAMA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 5A; CARDIOLIPIN ANTIBODY; MONOCLONAL ANTIBODY; PROTHROMBIN; THROMBIN; APC PROTEIN; BOWMAN BIRK INHIBITOR; CHROMOGENIC SUBSTRATE; CYTOSKELETON PROTEIN; DEXTRO PHENYLALANYLPIPECOLYLARGININE 4 NITROANILIDE; DIPEPTIDE; GLYCOPROTEIN; PROTEIN C; TRYPSIN INHIBITOR;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOTTING; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYDROLYSIS; LYMPHOCYTE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; TIME; DRUG ANTAGONISM; DRUG EFFECT; PHYSIOLOGY; TECHNIQUE;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, MONOCLONAL; BETA 2-GLYCOPROTEIN I; CHROMOGENIC COMPOUNDS; CYTOSKELETAL PROTEINS; DIPEPTIDES; GLYCOPROTEINS; HUMANS; METHODS; PROTEIN C; THROMBIN; TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN; TRYPSIN INHIBITORS;

EID: 0032590070     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199901)42:1<167::AID-ANR20>3.0.CO;2-B     Document Type: Article

References (41)

1. Bowie EJW, Thompson JH, Pascuzzi CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulant. J Clin Med 1963;62:416-21.
2. Much JR, Herbst KD, Rapaport SI. Thrombosis in patients with the 'lupus'-type circulating anticoagulant. Ann Intern Med 1980; 92:156-60.
3. Boey ML, Colaco CB, Charair AE, Elkon KB, Loizou S, Hughes GRV. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. BMJ 1983;87:1021-3.
4. Esmon CT, Owen WG. Identification of an cndothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A 1981;78:2249-52.
5. Stenflo J. Structure and function of protein C. Semin Thromb Haemost 1984;10:109-21.
6. Cariou R, Tobelem G, Bellucci S, Soria J, Soria C, Moclouf J, et al. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cell-inhibition of thrombomodulin dependent protein C activation. Thromb Haemost 1988;60:54-8.
7. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989;74:2426-32.
8. Malia RG, Kicken S, Greaves M, Prestone FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990;76:101-7.
9. Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism. Blood 1993;81:2618-25.
10. Pötzsch B, Kawamura H, Preissner KT, Schmidt M, Seeling C, Müller-Berghaus G. Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophillia in patients with lupus anticoagulant. J Lab Clin Med 1995;125:56-65.
11. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990;87:4120-4.
12. Galli M, Comfurius P, Maassen C, Hemker HC, De Baets MH, van Breda-Vriesman PJC, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-7.
13. Matsuura E, Igarashi Y, Fujimato M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990;336:177-8.
14. Heimburger N, Heide K, Haupt H, Schultze HE. Bausteinanalysen von Human Serum Proteinen. Clin Chim Acta 1964;10:293-302.
15. Kroll J, Larsen JK, Loft H, Ezban M, Wallewick K, Faber M. DNA binding proteins in Yoshida ascites tumor fluid. Biochim Biophys Acta 1976;434:490-501.
16. Polz E, Kostner GM. The binding of β2 glycoprotein-I to human serum lipoproteins: distribution among density fractions. FEBS Lett 1979;102:183-6.
17. Polz E, Wurm H, Kostner GM. Investigation on β2 glycoprotein-I in the rat: isolation from serum and demonstration in lipoprotein density fractions. Int J Biochem 1980;11:265-70.
18. Schousboe I. Characterization of the interaction between β2 glycoprotein-I and mitochondria, platelets, liposomes and bile acids. Int J Biochem 1983;15:1393-401.
19. Nimpf J, Wurm H, Kostner GM. Interaction of β2 glycoprotein-I with human blood platelets: influence upon ADP induced aggregation. Thromb Haemost 1985;54:397-401.
20. Schousboe I. β2 glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66:1086-91.
21. Nimpf J, Bevers EM, Bomans PHH, Till U, Wurm H, Kostner GM, et al. Prothrombinase activity of human platelets is inhibited by β2 glycoprotein-I. Biochim Biophys Acta 1986;884:142-9.
22. Keeling DM, Wilson AJG, Mackie IJ, Isenberg DA, Machin SJ. Role of β2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro. J Clin Pathol 1993;46:908-11.
23. Mori T, Takeya H, Nishioka J, Gabazza EC, Suzuki K. β2-glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Thromb Haemost 1996;75: 49-55.
24. Ichikawa K, Khamashta MA, Koike T, Matsuura E, Hughes GRV. β2-glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 1994;37:1453-61.
25. Brandt JT. Assay for phospholipid-dependent formation of thrombin and Xa: a potential method for quantifying lupus anticoagulant activity. Thromb Haemost 1991;66:453-8.
26. Van der Meer FJM, van Tilburg NH, van Wijngaarden A, van der Linden IK, Briët E, Bertina RM. A second plasma inhibitor of activated protein C: α1-antitrypsin. Thromb Haemost 1989;62: 756-62.
27. Heeb MJ, Gruber A, Griffin JH. Identification of divalent metal ion-dependent inhibition of activated protein C by α2-macroglobulin and α2-antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin, and plasmin. J Biol Chem 1991;266:17606-12.
28. Heeb MJ, Bischoff R, Courtney M, Griffin JH. Inhibition of activated protein C by recombinant α1-antitrypsin variants with substitution of arginine or leucine for methionine. J Biol Chem 1990;265:2365-9.
29. Suzuki K, Nishioka J, Hashimoto S. Protein C inhibitor: purification from human plasma and characterization. J Biol Chem 1983;258:163-8.
30. Radtke KP, Stief TW, Heimburger N. A new and simple isolation procedure for human protein C inhibitor. Biol Chem 1988;369: 965-74.
31. Stevenson KJ, Easton AC, Curry A, Thomson JM, Pollar L. The reliability of activated partial thromboplastin time methods and the relationship to lipid composition and ultrastructure. Thromb Haemost 1986;55:250-8.
32. Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995;95:309-16.
33. Goldsmith GH, Pierangeli SS, Branch DW, Gharavi AE, Harris EN. Inhibition of prothrombin activation by antiphospholipid antibodies. Br J Haematol 1994;87:548-54.
34. Schousboe I. Binding of β2-glycoprotein I to platelets: effect on adenylate cyclase activity. Thromb Res 1980;19:225-37.
35. Bancsi LFJMM, van der Linden IK, Bertina RM. β2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 1992; 67:649-53.
36. Oosting JD, Derksen RHWM, Hackeng TM, von Vliet M, Preissner KT, Bouma BN, et al. In vitro studies of antiphospholipid antibodies and its cofactor. β2-glycoprotein I. show negligible effects on endothelial cell mediated protein C activation. Thromb Haemost 1991;66:666-71.
37. Olee T, Pierangeli SS, Handley HH, The Le D, Wei X, Lai CJ, et al. A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice. Proc Natl Acad Sci U S A 1996;93:8606-11.
38. 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent β2-glycoprotein I and induce endothelial activation. Arthritis Rheum 1997;40:551-61.
39. Takeya H, Mori T, Gabazza EC, Kuroda K, Deguchi H, Matsuura E, et al. Anti-β2-glycoprotein I (β2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the β2GPI binding to phospholipid. J Clin Invest 1997;99:2260-8.
40. Arnout J, Wittevrongel C, Vanrusselt M, Hoylaerts M, Vermylen J. Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody beta-2-glycoprotein I complexes on phospholipid surfaces. Thromb Haemost 1998;79:79-86.
41. Atsumi T, Khamashta MA, Amengual O, Donohoe S, Mackie I, Ichikawa K, et al. Binding of anticardiolipin antibodies to protein C via β2glycoprotein I: a possible mechanism in the inhibitory effect of anticardiolipin antibodies on the protein C system. Clin Exp Immunol 1998;112:325-33.